Highbridge Capital Management LLC Theravance Biopharma, Inc. Transaction History

Highbridge Capital Management LLC

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 12, 2024	SELL	$8.58 - $11.4 $523,946 - $696,152	-61,066 Reduced 26.87%	166,234 $1.87 Million
Q3 2023 Nov 13, 2023	BUY	$8.38 - $10.44 $1.9 Million - $2.37 Million	227,300 New	227,300 $1.96 Million
Q1 2023 Aug 14, 2023	BUY	$9.87 - $11.44 $2.27 Million - $2.63 Million	230,100 New	230,100 $2.5 Million
Q1 2023 May 11, 2023	BUY	$9.87 - $11.44 $432,305 - $501,072	43,800 Added 23.51%	230,100 $2.5 Million
Q4 2022 Feb 13, 2023	SELL	$9.65 - $11.34 $373,455 - $438,858	-38,700 Reduced 17.2%	186,300 $2.09 Million
Q3 2022 Nov 14, 2022	BUY	$8.39 - $10.22 $1.89 Million - $2.3 Million	225,000 New	225,000 $2.28 Million
Q3 2021 Nov 12, 2021	SELL	$6.77 - $14.41 $3.98 Million - $8.47 Million	-587,666 Closed	0 $0
Q2 2021 Aug 12, 2021	BUY	$14.52 - $22.46 $8.53 Million - $13.2 Million	587,666 New	587,666 $8.53 Million

122

47.3M

200

12.8K

Ticker TBPH
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 66,782,400
Market Cap $640M
Description
Theravance Biopharma, Inc., a biopharmaceutical company, discovers, develops, and commercializes respiratory medicines in the United States, Europe, and Asia. The company offers YUPELRI, a once-daily, nebulized long-acting muscarinic antagonist used for the treatment of chronic obstructive pulmonary disease (COPD). Its product portfolio also inc...

Get notified when there are updates to the investment portfolio of Highbridge Capital Management LLC, based on Form 13F filings with the SEC.

Stay updated on Highbridge Capital Management LLC with notifications on news.